Exploring factors influencing anxiety and depression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research examines how various biopsychosocial factors, including thoughts, feelings, biology, and social support, contribute to the experiences of anxiety and depression. The study aims to identify why individuals respond differently to treatments and what influences their treatment adherence. It collects a wide range of data, including biological markers, psychological assessments, and social determinants of health, to create a comprehensive understanding of these mental health conditions. By analyzing these factors, the study seeks to improve treatment strategies for anxiety and depression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18 to 65 years of age.
* Each subject must have a level of understanding sufficient to agree to all required tests and examinations and sign an informed consent document.
* At the initial study enrollment, subjects must have fulfilled DSM-5 criteria for Major Depression, single episode or recurrent.
* At the initial study enrollment, subjects may have fulfilled DSM-5 criteria for an Anxiety Disorder Comorbid Psychiatric Disorders, specifically Anxiety Disorders (Panic Disorder, Specific Phobia, Social Anxiety Disorder, Generalized Anxiety Disorder), Obsessive Compulsive Disorder, or a prior diagnosis of Post-Traumatic Stress Disorder, and/or Attention Deficit Hyperactivity Disorder may be enrolled as per assessment and agreement of evaluating clinicians.
* Agree to participate in clinical treatment (medication management and psychotherapy)

Exclusion Criteria:

* Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.
* History of head trauma or stroke (also known as a cerebrovascular accident).
* Clinically significant abnormal laboratory tests.
* Subjects with one or more seizures without a clear and resolved etiology or current use of medication known to lower seizure threshold.
* Any use of opioid medication in the past 12 months
* Positive HIV test
* Current psychotic features or a diagnosis of Schizophrenia or any other psychotic disorder as defined in the DSM-IV.
* Subjects with a history of DSM-IV drug or alcohol dependency or abuse (except for caffeine or nicotine dependence) within the preceding 12 months. In addition, subjects who currently are using drugs (except for caffeine or nicotine) must not have used illicit substances or known drugs of abuse in the 2 weeks prior to screen
* Subjects who, in the investigator's judgment, pose a current serious suicidal or homicidal risk.

Where it's running

• Singula Institute, 353 Lexington Avenue (Room 600)
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Marc S Lener, M.D. — Ceo
• Study coordinator: Jen Tung, RN, MA
• Email: info@singulainstitute.org
• Phone: 2125315826

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Brain stimulation for anxiety and depression in children and teens

  This program will try transcranial magnetic stimulation (TMS) to see if it reduces anxiety and depression in children and teens aged 6 to 18 who are referred by their doctors.

  Recruiting University of Calgary · Calgary, Alberta · NCT06892847

• Evaluating mentalization-based psychotherapy for anxiety and depression

  This study is testing a new group therapy called mentalization-based psychotherapy to see if it helps people with anxiety and depression feel better compared to standard therapy.

  Recruiting Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · Málaga, Malaga · NCT06833567

• Cognitive training for anxiety, depression, and PTSD

  This study is testing a brain training program to see if it can help people with anxiety, depression, or PTSD think more clearly and feel better.

  Recruiting Phase 2/3 University of California, San Diego · San Diego, California · NCT06273527

• Investigating brain responses to threats in anxiety and depression

  This study is testing how an anti-anxiety medication affects the brain's response to threats in people with anxiety, depression, or both to better understand their differences and improve treatments.

  Recruiting Phase 4 Laureate Institute for Brain Research, Inc. · Tulsa, Oklahoma · NCT06004115

• Using RxWell to Reduce Opioid Use After Knee or Hip Surgery

  This study is testing whether a digital tool called RxWell can help people with mood disorders who are having knee or hip surgery reduce their opioid use and improve their mental health after the operation.

  Recruiting at 3 sites University of Pittsburgh · Monroeville, Pennsylvania and 2 other locations · NCT05658796

• Investigating brain response variability to predict success in online therapy for mental health

  This study is testing if changes in brain activity can help predict how well online therapy works for people with depression, anxiety, and insomnia.

  Recruiting Karolinska Institutet · Huddinge, Stockholm County · NCT04191811

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.